Praful R. Nair
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Praful R. Nair has a total of 81 co-authors. Here are the top co-authors by number of shared publications:
- Denis Wirtz
Department of Chemical and Biomolecular Engineering, The Johns Hopkins University, Baltimore, MD 21218, USA
30 shared publications - Arrate Muñoz-Barrutia
Universidad Carlos III de Madrid
27 shared publications - Estibaliz Gómez-De-Mariscal
AI-driven Optical Biology Laboratory, Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Oeiras, Portugal
27 shared publications - Alexandra Sneider
Department of Chemical and Biomolecular Engineering, Johns Hopkins Physical Sciences–Oncology Center and Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, Maryland
25 shared publications - Alexus Locke
Johns Hopkins Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, Maryland
25 shared publications - Bartholomew Starich
Department of Chemical and Biomolecular Engineering, Johns Hopkins University
25 shared publications
Latest Publications
- Open Access
Reprogramming CAR-T cell function through synthetic cytokine receptors suppresses metastatic progression of TNBC
Patient T cells modified with chimeric antigen receptors (CARs) have shown remarkable therapeutic success in previously incurable cancers. However, despite its success in hematological malignancies, CAR-T therapy has shown only modest efficacy in solid tumors. The medical field has focused on developing new molecular designs that enhance CAR-T persistence, prevent exhaustion in the tumor microenvironment (TME), and increase the specificity of the CAR-T cell to various tumor antigens. However, much less effort has been placed on enhancing CAR-T cells’ invasion into and migration through the stromal matrix of the TME, where they can elicit tumor-directed cytotoxicity. Here, we engineered CAR-T cells with synthetic cytokine receptors targeting inflammatory cytokines produced by the cells themselves, which increase their speed through collagen I matrices. We show that this enhanced motility is driven by increased CAR-T cell translocation through confined microchannels via cellular deformation, together with elevated migratory speeds in proximity to neighboring cells, suggesting improved responsiveness to local cues. These migration-enhanced CAR-T cells significantly reduce both primary tumor size and distant organ metastasis in triple-negative breast cancer (TNBC) mouse models compared to standard CAR-T cells. These results support molecular design strategies that exploit mechanisms to improve cellular therapies for metastatic solid tumors.
Open AccessReprogramming CAR-T cell function through synthetic cytokine receptors suppresses metastatic progression of TNBC
Patient T cells modified with chimeric antigen receptors (CARs) have shown remarkable therapeutic success in previously incurable cancers. However, despite its success in hematological malignancies, CAR-T therapy has shown only modest efficacy in solid tumors. The medical field has focused on developing new molecular designs that enhance CAR-T persistence, prevent exhaustion in the tumor microenvironment (TME), and increase the specificity of the CAR-T cell to various tumor antigens. However, much less effort has been placed on enhancing CAR-T cells’ invasion into and migration through the stromal matrix of the TME, where they can elicit tumor-directed cytotoxicity. Here, we engineered CAR-T cells with synthetic cytokine receptors targeting inflammatory cytokines produced by the cells themselves, which increase their speed through collagen I matrices. We show that this enhanced motility is driven by increased CAR-T cell translocation through confined microchannels via cellular deformation, together with elevated migratory speeds in proximity to neighboring cells, suggesting improved responsiveness to local cues. These migration-enhanced CAR-T cells significantly reduce both primary tumor size and distant organ metastasis in triple-negative breast cancer (TNBC) mouse models compared to standard CAR-T cells. These results support molecular design strategies that exploit mechanisms to improve cellular therapies for metastatic solid tumors.
- Open Access
Hyper-migratory CAR T cells alleviate ovarian cancer metastatic burden and improve prognosis
Cellular immunotherapy has shown remarkable efficacy in hematological malignancies but remains limited by infiltration issues in solid tumors, leading to poor treatment efficacy. We have recently shown that mesothelin-targeting CAR T cells co-transduced with cytokine-binding synthetic velocity receptors (VRs, referred to as CAR TV cells) demonstrate increased motility, improved infiltration in solid primary tumors, and lead to a better anti-tumor effect compared to CAR T cells that do not express VRs. However, it is metastasis that causes the vast majority of cancer related deaths and is difficult to target clinically, indicating an urgent unmet need. We show that these CAR T cells engineered to be hyper-migratory using VRs are highly effective against liver metastasis of ovarian cancer along different stages of the metastatic cascade. Mesothelin-targeting CAR TV cells expressing synthetic or native receptors responsive to the cytokine Interleukin-5 improved the survival of mice bearing an extremely high or ‘terminal’ level of metastatic burden compared to CAR T cells that did not express VRs. Against newly established metastatic lesions and lesions undergoing metastatic outgrowth, CAR TV cells showed a robust anti-cancer effect resulting in an improved prognosis compared to control CAR T cells. Histopathological assessments showed a substantial reduction of metastasis number and lesion size with CAR TV treatment, concomitant with increased immune cell infiltration in the metastatic regions. Our work demonstrates the efficacy of high-motility CAR T cells in a metastatic setting and extends their scope to the treatment of metastasis of solid tumors.
Open AccessHyper-migratory CAR T cells alleviate ovarian cancer metastatic burden and improve prognosis
Cellular immunotherapy has shown remarkable efficacy in hematological malignancies but remains limited by infiltration issues in solid tumors, leading to poor treatment efficacy. We have recently shown that mesothelin-targeting CAR T cells co-transduced with cytokine-binding synthetic velocity receptors (VRs, referred to as CAR TV cells) demonstrate increased motility, improved infiltration in solid primary tumors, and lead to a better anti-tumor effect compared to CAR T cells that do not express VRs. However, it is metastasis that causes the vast majority of cancer related deaths and is difficult to target clinically, indicating an urgent unmet need. We show that these CAR T cells engineered to be hyper-migratory using VRs are highly effective against liver metastasis of ovarian cancer along different stages of the metastatic cascade. Mesothelin-targeting CAR TV cells expressing synthetic or native receptors responsive to the cytokine Interleukin-5 improved the survival of mice bearing an extremely high or ‘terminal’ level of metastatic burden compared to CAR T cells that did not express VRs. Against newly established metastatic lesions and lesions undergoing metastatic outgrowth, CAR TV cells showed a robust anti-cancer effect resulting in an improved prognosis compared to control CAR T cells. Histopathological assessments showed a substantial reduction of metastasis number and lesion size with CAR TV treatment, concomitant with increased immune cell infiltration in the metastatic regions. Our work demonstrates the efficacy of high-motility CAR T cells in a metastatic setting and extends their scope to the treatment of metastasis of solid tumors.
- Open Access
3D map-guided modeling of functional endometrial tissue using multi-compartment assembloids
The human endometrium is a dynamic tissue that lines the uterus and undergoes constant remodeling, making it especially susceptible to gynecological diseases like endometriosis and endometrial cancer. The molecular mechanisms of these conditions are not well understood, partly due to the lack of in vitro models that mimic endometrial physiology, which limits options for targeted intervention and treatment of these diseases. Mouse models are also inadequate, as common laboratory strains do not naturally undergo a menstrual cycle comparable to that of humans. This study addresses this need by developing a 3D multi-compartment assembloid that mimics the architecture of endometrial tissue and recapitulates all three phases of the menstrual cycle (proliferative, secretory, and menstrual regression) within a single platform. The cellular and extracellular matrix (ECM) components in each compartment are carefully tuned based on a 3D spatial cellular map of endometrial tissue. The model contains endometrial epithelial cells enveloped in a basement membrane and endometrial stromal cells in a surrounding collagen-rich layer; this architecture allows realistic interactions between these cells and their respective ECMs. This assembloid successfully supports the controlled growth and organization of these cells, revealing reciprocal regulation of cell behavior and exhibiting compartment-specific hormonal responses, i.e., stromal decidualization. This platform enables the study of dynamic, phase-resolved, and compartment-specific paracrine signaling in human endometrial biology. By combining tissue-informed design, modular fabrication, and full-cycle hormonal responsiveness, this model sets a new benchmark for blastocyst implantation studies, organ modeling, and precision diagnostics in human reproductive health.
Open Access3D map-guided modeling of functional endometrial tissue using multi-compartment assembloids
The human endometrium is a dynamic tissue that lines the uterus and undergoes constant remodeling, making it especially susceptible to gynecological diseases like endometriosis and endometrial cancer. The molecular mechanisms of these conditions are not well understood, partly due to the lack of in vitro models that mimic endometrial physiology, which limits options for targeted intervention and treatment of these diseases. Mouse models are also inadequate, as common laboratory strains do not naturally undergo a menstrual cycle comparable to that of humans. This study addresses this need by developing a 3D multi-compartment assembloid that mimics the architecture of endometrial tissue and recapitulates all three phases of the menstrual cycle (proliferative, secretory, and menstrual regression) within a single platform. The cellular and extracellular matrix (ECM) components in each compartment are carefully tuned based on a 3D spatial cellular map of endometrial tissue. The model contains endometrial epithelial cells enveloped in a basement membrane and endometrial stromal cells in a surrounding collagen-rich layer; this architecture allows realistic interactions between these cells and their respective ECMs. This assembloid successfully supports the controlled growth and organization of these cells, revealing reciprocal regulation of cell behavior and exhibiting compartment-specific hormonal responses, i.e., stromal decidualization. This platform enables the study of dynamic, phase-resolved, and compartment-specific paracrine signaling in human endometrial biology. By combining tissue-informed design, modular fabrication, and full-cycle hormonal responsiveness, this model sets a new benchmark for blastocyst implantation studies, organ modeling, and precision diagnostics in human reproductive health.
- Open Access
- 9 May 2024
- Published by American Association for Cancer Research (AACR)
Figure S4 from Small Extracellular Vesicles Promote Stiffness-mediated Metastasis
Plastic EVs have different biodistribution compared to stiff and soft EVs.
- 9 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Small Extracellular Vesicles Promote Stiffness-mediated Metastasis
Plastic EVs have different biodistribution compared to stiff and soft EVs.
- Open Access
- 9 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Methods from Small Extracellular Vesicles Promote Stiffness-mediated Metastasis
- 9 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods from Small Extracellular Vesicles Promote Stiffness-mediated Metastasis
- Open Access
- 9 May 2024
- Published by American Association for Cancer Research (AACR)
FIGURE 3 from Small Extracellular Vesicles Promote Stiffness-mediated Metastasis
Stiff EVs show increased biodistribution and retention in vivo.A, Schematic of EV isolation and staining prior to tail-vein injection of 10 µg of EVs in nude mice. NIR imaging (B) and mean SNR (C) of MDA-MB-231 vesicle biodistribution in dorsal, left, ventral, and right sides (mean ± SEM). Signal intensity is in arbitrary units (a.u.). Three mice in 0.5 kPa condition, and four in 25 kPa condition; one-way ANOVA. NIR imaging (D) and mean SNR biodistribution (E) in the lungs, liver, spleen, kidneys, and bone/bone marrow (mean ± SEM). Signal intensity is in arbitrary units (a.u.). Three mice in MDA-MB-231 0.5 kPa condition and four in 25 kPa condition; one-way ANOVA. F, MDA-MB-231 EV binding assay to ECM proteins collagen type I, collagen type IV, and laminin (mean ± SEM). Three biological repeats for collagen type I and collagen type IV; five for laminin. Paired t test.
- 9 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 3 from Small Extracellular Vesicles Promote Stiffness-mediated Metastasis
Stiff EVs show increased biodistribution and retention in vivo.A, Schematic of EV isolation and staining prior to tail-vein injection of 10 µg of EVs in nude mice. NIR imaging (B) and mean SNR (C) of MDA-MB-231 vesicle biodistribution in dorsal, left, ventral, and right sides (mean ± SEM). Signal intensity is in arbitrary units (a.u.). Three mice in 0.5 kPa condition, and four in 25 kPa condition; one-way ANOVA. NIR imaging (D) and mean SNR biodistribution (E) in the lungs, liver, spleen, kidneys, and bone/bone marrow (mean ± SEM). Signal intensity is in arbitrary units (a.u.). Three mice in MDA-MB-231 0.5 kPa condition and four in 25 kPa condition; one-way ANOVA. F, MDA-MB-231 EV binding assay to ECM proteins collagen type I, collagen type IV, and laminin (mean ± SEM). Three biological repeats for collagen type I and collagen type IV; five for laminin. Paired t test.
- Open Access
- 9 May 2024
- Published by American Association for Cancer Research (AACR)
FIGURE 4 from Small Extracellular Vesicles Promote Stiffness-mediated Metastasis
Stiff EVs promote cancer cell migration and dissemination. A, Schematic of 2-day GFP+ zebrafish embryo model system used to test the ability of MDA-MB-231 EVs (red, filled triangles) to disperse MDA-MB-231 cancer cells (blue, open triangles). Scale bar, 100 µm. B, Full zebrafish body images of the embryos at time 0 and 24 hours postinjection of MDA-MB-231 cancer cells. Scale bar, 100 µm. Representative images. C, Enlarged images of disseminated MDA-MB-231 cells (white) and EVs (red). Scale bar, 100 µm. Representative images. D, Percentage of injected embryos with cancer cell dissemination to the head or the tail. Total number of fish per condition is 47 for PBS control, 63 for 25 kPa, and 78 for 0.5 kPa condition. Five biological repeats of EVs. One-way ANOVA.
- 9 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 4 from Small Extracellular Vesicles Promote Stiffness-mediated Metastasis
Stiff EVs promote cancer cell migration and dissemination. A, Schematic of 2-day GFP+ zebrafish embryo model system used to test the ability of MDA-MB-231 EVs (red, filled triangles) to disperse MDA-MB-231 cancer cells (blue, open triangles). Scale bar, 100 µm. B, Full zebrafish body images of the embryos at time 0 and 24 hours postinjection of MDA-MB-231 cancer cells. Scale bar, 100 µm. Representative images. C, Enlarged images of disseminated MDA-MB-231 cells (white) and EVs (red). Scale bar, 100 µm. Representative images. D, Percentage of injected embryos with cancer cell dissemination to the head or the tail. Total number of fish per condition is 47 for PBS control, 63 for 25 kPa, and 78 for 0.5 kPa condition. Five biological repeats of EVs. One-way ANOVA.
- Open Access
- 9 May 2024
- Published by American Association for Cancer Research (AACR)
Figure S1 from Small Extracellular Vesicles Promote Stiffness-mediated Metastasis
Stiffness measurements of primary patient tissues
- 9 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Small Extracellular Vesicles Promote Stiffness-mediated Metastasis
Stiffness measurements of primary patient tissues
- Open Access
- 9 May 2024
- Published by American Association for Cancer Research (AACR)
Table S1 from Small Extracellular Vesicles Promote Stiffness-mediated Metastasis
Table S1 - Primers for qRT-PCR analysis
- 9 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Small Extracellular Vesicles Promote Stiffness-mediated Metastasis
Table S1 - Primers for qRT-PCR analysis
- Open Access
- 9 May 2024
- Published by American Association for Cancer Research (AACR)
FIGURE 1 from Small Extracellular Vesicles Promote Stiffness-mediated Metastasis
Matrix stiffness impacts the quantity of EVs produced by patient tissue. A, Representative primary breast tumor tissue. Sample has been mechanically mapped using microindentation. Dark circles indicate measurements of the elastic modulus expressed in units of kPa. Crosses are nonmeasurable indentations. Dotted lines indicate where the tissue was sectioned into stiff (middle) and soft (right) regions for subsequent vesicle collection. B, Mean compression measurements (kPa, mean ± SEM) of patient tumor and adjacent normal tissues. Ten adjacent normal tissue samples and nine tumor tissue samples. Nonparametric t test. C, Vesicles released per gram of tissue in pathologist determined tumor adjacent or tumor tissue patient samples. Ten normal tissue samples and eight tumor tissue samples. D, Combined tumor-adjacent and tumor tissues samples separated by mean compression measurements (kPa, mean ± SEM). Fourteen samples < 10 kPa and four samples > 10 kPa. E, Tumor samples separated by mean microindentation measurements (kPa, mean ± SEM). Thirteen samples < 10 kPa and six samples > 10 kPa. Nonparametric t test.
- 9 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 1 from Small Extracellular Vesicles Promote Stiffness-mediated Metastasis
Matrix stiffness impacts the quantity of EVs produced by patient tissue. A, Representative primary breast tumor tissue. Sample has been mechanically mapped using microindentation. Dark circles indicate measurements of the elastic modulus expressed in units of kPa. Crosses are nonmeasurable indentations. Dotted lines indicate where the tissue was sectioned into stiff (middle) and soft (right) regions for subsequent vesicle collection. B, Mean compression measurements (kPa, mean ± SEM) of patient tumor and adjacent normal tissues. Ten adjacent normal tissue samples and nine tumor tissue samples. Nonparametric t test. C, Vesicles released per gram of tissue in pathologist determined tumor adjacent or tumor tissue patient samples. Ten normal tissue samples and eight tumor tissue samples. D, Combined tumor-adjacent and tumor tissues samples separated by mean compression measurements (kPa, mean ± SEM). Fourteen samples < 10 kPa and four samples > 10 kPa. E, Tumor samples separated by mean microindentation measurements (kPa, mean ± SEM). Thirteen samples < 10 kPa and six samples > 10 kPa. Nonparametric t test.